Alantra advised Laboratorios Buxton on the sale of the company to Brazil’s Eurofarma
Alantra advised the shareholders of Laboratorios Buxton on the sale of the company to Brazil’s Eurofarma.
Buxton is an Argentine pharmaceutical laboratory founded in 2003 by Roberto Busnelli (former shareholder of Rontag), engaged in the production, marketing and sale of own prescription medicines to specific segments of the Argentine pharmaceutical market. Buxton main therapeutic areas include (i) central nervous system (neurology/psychiatry), (ii) fertility, (iii) urology, and (iv) rheumatology. Buxton’s product portfolio includes own products – approx. 50% of revenues, mainly in neurology and rheumatology – and products licensed from international companies specialized in certain therapeutic areas – approx. 50% of revenues, mainly in fertility and urology-.
Eurofarma is one of the largest pharmaceutical companies in Brazil. With operations in more than 20 countries in South and Central America, the Caribbean and Africa, and 9 manufacturing plants strategically located in Latin America, Eurofarma is positioned in the major pharmaceutical segments: Medical Prescription and OTC, Generics, Hospital, Bidding, Oncology, Third Party Services and Veterinary. The company has a broad portfolio that meets all medical specialties, and which is a reference in the central nervous system, anti-infective and hormonal drugs.
Oct 2020Buy-side advisoryOct 2020SECTOR HealthcareService M&A
Oct 2020InvestmentOct 2020SECTOR HealthcareService Strategic Advisory
Sep 2020Buy-side advisoryValue CHF 435 millionSep 2020SECTOR HealthcareService M&AValue CHF 435 million
Sep 2020Sell-side advisorySep 2020SECTOR HealthcareService M&A